

Bone Therapeutics announces results of Annual General Meeting

Significantly strengthened its Board of Directors with appointment of Gloria Matthews as Independent Director

Shareholders also approved all other resolutions

Gosselies, Belgium, 12 June 2019, 6pm CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapeutics to address high unmet medical needs in orthopaedics and bone diseases, announces the results of its Annual General Meeting (AGM) held today at the Company's headquarters in Gosselies.

The resolutions approved today included the appointment of Gloria Matthews, DVM⁽¹⁾, PhD, DACVS⁽²⁾, an American citizen, as Independent Director. Gloria has more than 20 years of research and clinical experience in orthopaedics, osteoarthritis, rheumatology and cartilage repair with extensive expertise in medical devices, biologicals, and regenerative medicine. She has a strong track record of supporting life sciences companies to grow and evolve from start-up stage to fully integrated biopharma companies and has built an impressive business and medical network over the years. She was Senior Vice President of MiMedx, a biopharma company focused on the development and commercialisation of regenerative and therapeutic biologicals in wound care, and spine and sports medicine. Prior to that, she was Chief Medical Officer of the restorative cell therapy company Histogenics and Senior Director of Orthopaedics at Genzyme, a Sanofi company.

In addition to the appointment of Gloria Matthews, the AGM acknowledged the resignation of Michel Helbig de Balzac from the Board of Directors as well as the end of the mandates of Dirk Dembski and Roland Baron. The changes in Board composition are in line with the company strategy to increase diversity in both gender and expertise. The Board of Directors now comprises seven members, of whom two are women.

Welcoming Gloria Matthews to the Board, Jean Stéphenne, Chairman, said: *"We are very pleased to have someone of Gloria's calibre joining our Board of Directors. We are convinced that her network, proven track record and disease relevant in-depth expertise and strategic insights will be of important value as we enter the next stage for the Company and further advance our unique product pipeline towards Phase III clinical development. I would also like to personally thank Michel, Roland and Dirk for their invaluable support, dedication and leadership in transforming the Company into a leading biotech company focused on innovative treatment solutions in orthopaedics and bone diseases."*

Gloria Matthews commented: *"I am convinced of the Company's potential to revolutionize treatment options in orthopaedics and bone diseases, and to significantly improve current standard of care. Having observed the Company's progress over the past 2 years, I am excited to now play a role in the acceleration of this growth. I am therefore delighted to join the Board and I look forward to working with the team to execute on the long-term growth strategy and to contributing to the Company's future successes."*

The final results of the Annual General Meeting will be made available on the Company's website.

⁽¹⁾ Doctor of Veterinary Medicine

⁽²⁾ Doctor American College of Veterinary Surgeons

● **About Bone Therapeutics**

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy and an innovative biological product in later-stage clinical development across a number of disease areas, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics' core technology is based on its allogeneic cell therapy platform (ALLOB) which uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, cutting-edge manufacturing process.

The Company's ALLOB product pipeline includes a cell therapy product candidate that is expected to enter Phase II/III clinical development for the treatment of delayed-union fractures and a Phase II asset in patients undergoing a spinal fusion procedure. In addition, the Company is also developing an enhanced viscosupplement, JTA-004, which is expected to enter Phase III development for the treatment of pain in knee osteoarthritis.

Bone Therapeutics' cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. Further information is available at www.bonetherapeutics.com.

● **For further information, please contact:**

Bone Therapeutics SA

Thomas Lienard, Chief Executive Officer
Jean-Luc Vandebroek, Chief Financial Officer
Gunther De Backer, Head of Corporate Communications and Investor Relations

Tel: +32 (0) 71 12 10 00

investorrelations@bonetherapeutics.com

For International Media Enquiries:

Consilium Strategic Communications

Marieke Vermeersch

Tel: +44 (0) 20 3709 5701

bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries:

NewCap Investor Relations & Financial Communications

Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau

Tel: + 33 (0)1 44 71 94 94

bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
